PRINCETON, N.J. and SUZHOU, China, November 28, 2025 -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it is going to present updated efficacy analysis of Cohort G by CLDN18.2 and PD-L1 expression from a phase I/II Study of first-line Osemitamab (TST001) plus Nivolumab and CAPOX for advanced G/GEJ cancer (TranStar102) at ESMO Asia. 

A brief summary of the presentation is as follows:

Title: First-line Osemitamab plus Nivolumab and CAPOX for Advanced G/GEJ Cancer (TranStar102) – Updated Efficacy Analysis of Cohort G by CLDN18.2 and PD-L1 Expression from a Phase I/II Study

Abstract#: 299P

Session Type: Poster 

Session Title: Poster display session and cocktail

Session Date and Time: December 5, 2025, 17:15 to 18:15 (UTC+8)

First Author: Dan Liu, Beijing Cancer Hospital

About Osemitamab (TST001)

Osemitamab (TST001) is a high affinity humanized anti-CLDN18.2 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity ("ADCC"). It has shown potent anti-tumor activities in tumor xenograft models. Osemitamab (TST001) is the second CLDN18.2 targeting antibody being developed globally. Osemitamab (TST001) was generated using Transcenta's Immune Tolerance Breaking Technology (IMTB) platform. Osemitamab (TST001) kills CLDN18.2 expressing tumor cells by mechanisms of ADCC. Leveraging advanced bioprocessing technology, the fucose content of Osemitamab (TST001) was significantly reduced during the production, which further enhanced NK cells mediated ADCC activity of Osemitamab (TST001). Osemitamab (TST001) has been granted Orphan Drug Designation in the U.S. by FDA for the treatment of patients with gastric or gastroesophageal junction (G/GEJ) and pancreatic cancer.